Literature DB >> 19484179

[Stroke and atrial fibrillation].

G Gahn1.   

Abstract

Approximately 80% of all strokes are ischemic, the remaining being hemorrhagic. The major reason for cerebral ischemia is occlusion of a cerebral artery by a cardiac thrombus in a patient with atrial fibrillation. This article focuses on the therapeutic management of patients with cerebral ischemia due to atrial fibrillation and is based on the guidelines of the German Society of Neurology and the European Stroke Organization: Patients with cerebral ischemia and atrial fibrillation require oral anticoagulation with an INR of 2.0-3.0. After a TIA (transient ischemic attack) or minor ischemic stroke, anticoagulation can be initiated within the first week after the stroke. Combination therapy of aspirin and clopidogrel is less effective than oral anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484179     DOI: 10.1007/s00399-009-0045-6

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  34 in total

Review 1.  Patterns of ischaemic cerebral diseases.

Authors:  José M Ferro
Journal:  J Neurol       Date:  2004-01       Impact factor: 4.849

2.  Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischemic attack or stroke.

Authors:  Sebastiaan F T M de Bruijn; Willem R P Agema; Gert Jan Lammers; Ernst E van der Wall; Ron Wolterbeek; Eduard R Holman; Edward L E M Bollen; Jeroen J Bax
Journal:  Stroke       Date:  2006-08-31       Impact factor: 7.914

3.  Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials.

Authors:  Maurizio Paciaroni; Giancarlo Agnelli; Sara Micheli; Valeria Caso
Journal:  Stroke       Date:  2007-01-04       Impact factor: 7.914

4.  Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.

Authors:  Paul T Akins; Harvey A Feldman; Robert G Zoble; David Newman; Stefan G Spitzer; Hans-Christoph Diener; Gregory W Albers
Journal:  Stroke       Date:  2007-01-25       Impact factor: 7.914

5.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

6.  Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.

Authors:  P M Bath; E Lindenstrom; G Boysen; P De Deyn; P Friis; D Leys; R Marttila; J Olsson; D O'Neill; J Orgogozo; B Ringelstein; J van der Sande; A G Turpie
Journal:  Lancet       Date:  2001-09-01       Impact factor: 79.321

7.  Preventive health care, 1999 update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. Canadian Task Force on Preventive Health Care.

Authors:  M K Kapral; F L Silver
Journal:  CMAJ       Date:  1999-10-19       Impact factor: 8.262

Review 8.  Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Alan S Go; Jonathan L Halperin; Warren J Manning
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 9.  Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review.

Authors:  Joy Liao; Zahira Khalid; Ciaran Scallan; Carlos Morillo; Martin O'Donnell
Journal:  Stroke       Date:  2007-09-27       Impact factor: 7.914

10.  Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study.

Authors:  Ka Sing Wong; Christopher Chen; Ping Wing Ng; Tak Hong Tsoi; Ho Lun Li; Wing Chi Fong; Jonas Yeung; Chi Keung Wong; Kin Keung Yip; Hong Gao; Hwee Bee Wong
Journal:  Lancet Neurol       Date:  2007-05       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.